Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07780656
PHASE3

A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)

Sponsor: GlaxoSmithKline

View on ClinicalTrials.gov

Summary

The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.

Official title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants 40 to 80 Years of Age With Moderate to Very Severe COPD (PERSIST COPD-2)

Key Details

Gender

All

Age Range

40 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

624

Start Date

2026-08-31

Completion Date

2030-03-15

Last Updated

2026-08-21

Healthy Volunteers

No

Interventions

DRUG

GSK5784283

GSK5784283 will be administered.

DRUG

Placebo

Placebo will be administered.

DRUG

Standard of care

Standard of care will be administered.